Azitra Inc (AZTR): שווי כולל של נכסי החברה

Azitra, Inc. is expanding its partnership with Bayer to study the skin microbiome and develop therapies for severe dermatoses. The company's operations within US jurisdiction eliminate sanction risks, maintaining a neutral backdrop. Growth is driven by the success of the ATR-12 candidate in treating the rare Netherton syndrome and FDA approvals. Total assets amount to 6.43, which is clearly demonstrated by the chart of exchange quotes reflecting the total value of resources.

Assessing the quality of resources at Azitra, Inc. requires an analysis of the organization's total asset dynamics, which is reverse-calculated via ROA to capture the aggregate of equity and debt capital. This indicator reflects the investment density in the development of GMO bacteria and partner research on skin proteins, where the growth in asset value correlates directly with the company's scientific and technological potential and its investment attractiveness for future M&A transactions.